Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Featured trial
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

myelodysplastic syndrome (mds)
anemia
myelodysplastic syndromes
aplastic anemia
anemia studies
  • 172 views
  • 22 Dec, 2020
  • 1 location
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Background Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells. Standard treatment for SSA is a combination of 3 drugs (Cyclosporine [CsA], Eltrombopag [EPAG], and horse anti-thymocyte globulin [h-ATG]). Researchers want to see if starting people at …

immunosuppressant
cyclosporine
reticulocyte count
horse anti-thymocyte globulin
platelet count
  • 12 views
  • 14 May, 2022
  • 1 location
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

hematopoietic growth factors
biologic agent
bcr/abl
monoclonal antibodies
white blood cell count
  • 254 views
  • 15 May, 2022
  • 38 locations
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

The purpose of this study is to evaluate that whether the AML (acute myeloid leukemia)-CAMS (Chinese Academy of Medical Sciences)-2016 regimen, includes risk-stratified therapy and the use of Dasatinib in CBF (Core binding factor)-AML, can improve the outcome in childhood AML.

consolidation therapy
remission
  • 26 views
  • 23 Feb, 2022
  • 1 location
TPO-Mimetic Use in Children for Hemotopoietic Failure

This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders including acquired and inherited conditions as a first line of therapy along with standard of …

romiplostim
platelet transfusion
monosomy 7
blood transfusion
leukemia
  • 0 views
  • 18 Jun, 2021
  • 1 location
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Background Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

immunosuppressant
cyclosporine
reticulocyte count
anemia
horse anti-thymocyte globulin
  • 114 views
  • 21 Apr, 2022
  • 1 location
Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML

Conventional cytogenetic studies have been the gold standard for more than five decades for detecting genetic alterations that are greater than 10 Mb (mega base pairs) in size. Conventional cytogenetic studies have paved the way in identifying specific chromosomal aberrations associated with clinically and morphologically definitive subsets of hematological neoplasms. …

acute promyelocytic leukemia
  • 0 views
  • 15 Mar, 2022
  • 1 location